Regulus

Regulus reports positive findings from Phase I kidney disease trial
Regulus reports positive findings from Phase I kidney disease trial
Clinical Trials Arena
Regulus
kidney disease
RGLS8429
clinical trials
Flag link:
Sanofi walks away from kidney disease therapy, leaving $25M in milestones out of reach for Regulus
Sanofi walks away from kidney disease therapy, leaving $25M in milestones out of reach for Regulus
Fierce Biotech
Sanofi
kidney disease
Regulus
lademirsen
Flag link:
Regulus lays off 60% of staff, halts development
Regulus lays off 60% of staff, halts development
Biopharma Dive
Regulus
layoffs
restructuring
RG-012
Sanofi Genzyme
Flag link:
Regulus reports a trio of pipeline setbacks
Regulus reports a trio of pipeline setbacks
BioPharma Dive
Regulus
RG-101
RGLS5040
RG-105
cholestatic disease
type 2 diabetes
hepatitis C
Flag link:
Regulus Dumps Two Drugs, AstraZeneca Sends Back Another, Shares Fall
Regulus Dumps Two Drugs, AstraZeneca Sends Back Another, Shares Fall
Xconomy
Regulus
AstraZeneca
Flag link:
Regulus Hep C Drug Stays On Clinical Hold
Regulus Hep C Drug Stays On Clinical Hold
Investopedia
Regulus
hepatitis C
RG-101
Flag link:
Regulus hits further setbacks as clinical hold upheld
Regulus hits further setbacks as clinical hold upheld
BioPharma Dive
Regulus
clinical trials
RG-101
hepatitis C
Flag link:
FDA halts testing of Regulus' Hep C drug, sending shares into tailspin
FDA halts testing of Regulus' Hep C drug, sending shares into tailspin
BioPharma Dive
FDA
Regulus
hepatitis C
clinical trials
RG-101
Flag link:
The Top 4 Biopharma Movers of the Past Week
The Top 4 Biopharma Movers of the Past Week
24/7 Wall St
Ocular Therapeutix
Regulus
Zafgen
Aerie Pharma
Flag link:
Should Gilead Investors Fear Regulus?
Should Gilead Investors Fear Regulus?
Seeking Alpha
Gilead Sciences
Regulus
hepatitis C
Harvoni
RG-101
Flag link:
Regulus Bolsters Argument for Effective Hepatitis C Injection
Regulus Bolsters Argument for Effective Hepatitis C Injection
TheStreet.com
Regulus
hepatitis C
RG-101
Flag link:
3 Key FDA Decisions Expected in February
3 Key FDA Decisions Expected in February
24/7 Wall St
FDA
Vertex Pharmaceuticals
Kalydeco
Regulus
RG-101
Sarepta Therapeutics
eteplirsen
Flag link:
Regulus tanks on CEO's exit as investors fear a bad omen
Regulus tanks on CEO's exit as investors fear a bad omen
Fierce Biotech
Regulus
Flag link:
[video]2 Small Biotech Stocks Dreaming Big in Hepatitis C
[video]2 Small Biotech Stocks Dreaming Big in Hepatitis C
Motley Fool
hepatitis C
Regulus
Achillion
Flag link:
Regulus slides after hep C contender's results underwhelm investors
Regulus slides after hep C contender's results underwhelm investors
Fierce Biotech
Regulus
hepatitis C
RG-101
microRNA
Flag link:
How 1 Tiny Hepatitis C Drug Developer Trounced Gilead Sciences, Inc. in 2014
How 1 Tiny Hepatitis C Drug Developer Trounced Gilead Sciences, Inc. in 2014
Motley Fool
hepatitis C
Gilead Sciences
Regulus
Harvoni
Sovaldi
RG-101
Flag link:
Regulus Therapeutics more than doubles on early data for microRNA treatment for hepatitis C
Regulus Therapeutics more than doubles on early data for microRNA treatment for hepatitis C
Yahoo/AP
Regulus
hepatitis C
microRNA
RG-101
Flag link:
Which Companies Are In Michael King's Oncology Wheelhouse?
Which Companies Are In Michael King's Oncology Wheelhouse?
Seeking Alpha
Alnylam
Regulus
Isis Pharmaceuticals
SynaGeva BioPharma
Sarepta Therapeutics
Onyx
Celgene
Millennium
Takeda
Ariad Pharmaceuticals
Pharmacyclics
Astex
Flag link:
Regulus Therapeutics: Serious Red Flags At This Public Offering
Regulus Therapeutics: Serious Red Flags At This Public Offering
Seeking Alpha
Regulus
stock offering
Sanofi
GSK
AstraZeneca
Flag link:
IPO Preview: Regulus Therapeutics
IPO Preview: Regulus Therapeutics
Seeking Alpha
IPOs
Regulus
AstraZeneca
Flag link:

Pages